ArticleCardio-oncology (London, England)2025
Novel use of stereotactic ablative radiotherapy for refractory ventricular tachycardia with cardiac metastasis of primary renal cell carcinoma: a case report.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: A narrative review and pooled analysis of clinical outcomes and treatment delivery approaches.Journal of applied clinical medical physics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough rare, cardiac metastases are increasingly reported in oncology. Surgery may be an option for selected patients, but is often not feasible due to high postoperative morbidity. Radiotherapy therefore emerges as a non-invasive local treatment, either as a primary or adjuvant approach, similar to its use in other palliative settings. CASE PRESENTATION: We report the case of a patient with a cardiac metastasis from metastatic renal cell carcinoma, initially revealed by a life-threatening arrhythmic storm resulting in cardiac arrest. Given the arrhythmia’s resistance to conventional therapies—including antiarrhythmic drugs and radiofrequency ablation—stereotactic body radiotherapy (SBRT) was administered, targeting the cardiac lesion. This is only the second reported case of SBRT for a cardiac metastasis responsible for severe rhythm disturbances and there has never been a case report of SBRT delivered at such a high dose to a cardiac metastasis of this size. The procedure was well tolerated without immediate complications and showed initial therapeutic efficacy. However, the patient later experienced a recurrence of arrhythmia, which ultimately led to the patient’s death.
conclusionThis case highlights the potential role of SBRT as a salvage therapy for cardiac metastases, which remain a challenging and often fatal condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.